Abstract: Disclosed is an intrauterine system (100, 300, 400, 500, 600) comprising a frame (102, 302, 402, 502, 602), a removal thread (218, 326, 436, 626) and at least one pharmaceutically active agent. The frame has a first end (104, 304, 404, 504, 604), a second end (106, 306, 406, 506, 606) and a length L. The first end of the frame comprises a first locking part (108, 308, 408, 508, 608) and the second end of the frame comprises a second locking part (110, 310, 410, 510, 610), the first locking part and the second locking part being arranged to form a lock (202, 312, 432). The removal thread is attached to the first end of the frame. The removal thread is configured to guide the first locking part to the second locking part. Further, disclosed is a kit comprising the aforementioned intrauterine system and an inserter.

Abstract: The invention relates to a method for altering the release characteristics of a long acting drug delivery device containing at least two drugs in different segments, wherein the segments are arranged to a specific sequence. The invention furthermore relates to a drug delivery device with reduced initial burst containing two different drugs in different segments. The invention further relates to a delivery device manufactured according to the a.m. method and its use in contraception and gynecological therapies.

Abstract: The invention relates to a method for altering the release characteristics of a long acting drug delivery device containing at least two drugs in different segments, wherein the segments are arranged to a specific sequence. The invention furthermore relates to a drug delivery device with reduced initial burst containing two different drugs in different segments. The invention further relates to a delivery device manufactured according to the a.m. method and its use in contraception and gynecological therapies.

Abstract: The invention relates to a method for producing a drug delivery device, which has a body comprising a siloxane-based elastomer and at least one active agent. The method comprises applying adhesive material, which comprises non-cured siloxane based elastomer, into a contact with the body and curing the said adhesive material by subjecting it to radiation energy from a laser source. The invention relates also to a drug delivery device manufactured according to the method.

Abstract: The invention relates to a method for producing a drug delivery device, which has a body comprising a siloxane-based elastomer and at least one active agent. The method comprises applying adhesive material, which comprises non-cured siloxane based elastomer, into a contact with the body and curing the said adhesive material by subjecting it to radiation energy from a laser source. The invention relates also to a drug delivery device manufactured according to the method.

Abstract: The invention relates to a method for altering the release characteristics of a long acting drug delivery device containing at least two drugs in different segments, wherein the segments are arranged to a specific sequence. The invention furthermore relates to a drug delivery device with reduced initial burst containing two different drugs in different segments. The invention further relates to a delivery device manufactured according to the a.m. method and its use in contraception and gynecological therapies.

Abstract: The present invention relates to an improved method of contraception which addresses the problems of initial bleeding and spotting associated with the use of intrauterine delivery systems, and to an improved intrauterine delivery system.

Abstract: The present invention for the treatment of endometriosis relates to providing a parenteral dosage form (delivery system) for the controlled release of an aromatase inhibitor (AI) in a daily release rate that does not induce stimulation of the ovaries by negative feed-back of the pituitary-ovarian-axis (which would cause secretion of gonadotropins and stimulation of ovarian follicular growth) and a gestagen in a daily release rate below the ovulation inhibition dose that provides contraceptive efficacy based on local effects (e.g. reducing and thickening of the cervical mucus impairing sperm ascension, effects on the endometrium and on tubal motility impairing implantation and egg transport).

Abstract: The present invention for the treatment of endometriosis relates to providing a parenteral dosage form (delivery system) for the controlled release of an aromatase inhibitor (AI) in a daily release rate that does not induce stimulation of the ovaries by negative feed-back of the pituitary-ovarian-axis (which would cause secretion of gonadotropins and stimulation of ovarian follicular growth) and a gestagen in a daily release rate below the ovulation inhibition dose that provides contraceptive efficacy based on local effects (e.g. reducing and thickening of the cervical mucus impairing sperm ascension, effects on the endometrium and on tubal motility impairing implantation and egg transport).

Abstract: The present invention is related to an intravaginal delivery system for the controlled release of drospirenone and an estrogen, optionally also comprising one or more therapeutically active or a health-promoting substance capable of giving and/or enhancing protection against bacterial and fungal infections, and/or enhancing protection against sexually transmitted diseases. The delivery system consists of one or more compartments, one of each comprising a core and a membrane encasing the core, said core and membrane essentially consisting of a same or different polymer composition, wherein at least one compartment comprises drospirenone ant at least one compartment which may be the same or different from the one comprising drospirenone, comprises an estrogen or a mixture of drospirenone and an estrogen, and wherein the membrane or the surface of the membrane or at least one of the cores comprises said therapeutically active or a health-promoting substance.

Abstract: The present invention is related to an intravaginal delivery system for the controlled release of drospirenone and an estrogen, optionally also comprising one or more therapeutically active or a health-promoting substance capable of giving and/or enhancing protection against bacterial and fungal infections, and/or enhancing protection against sexually transmitted diseases. The delivery system consists of one or more compartments, one of each comprising a core and a membrane encasing the core, said core and membrane essentially consisting of a same or different polymer composition, wherein at least one compartment comprises drospirenone ant at least one compartment which may be the same or different from the one comprising drospirenone, comprises an estrogen or a mixture of drospirenone and an estrogen, and wherein the membrane or the surface of the membrane or at least one of the cores comprises said therapeutically active or a health-promoting substance.

Abstract: A disposable device for inserting one or more implants, the device including a tublar cannula (10) having a tip (11), the cannula also serving as a container for the implants, a plunger (20) and a handle (30) having a first end (31) directed towards the cannula, and a second end (32) directed away from the cannula. The plunger and handle are attached or attachable to each other in fixed manner, and the cannula is arranged to be movable in the longitudinal direction, so that the plunger is placed within. The cannula can, after inserting the implant or implants, be drawn on top of the plunger (20) so far that tip (11) becomes covered by handle (30) or by a piece connected to handle (30), and/or cannula (10) is, when drawn to its extreme position, towards second end (32) of handle (30), arranged to be irretrievably locked in relation to plunger (20).

Abstract: The invention relates to a disposable device for inserting one or several implants, said device comprising a tubular cannula (10) provided with a tip (11), said cannula also serving as a container for the implants, a plunger (20) and a handle (30) having a first end (31) directed towards the cannula (10), and a second end (32) directed away from the cannula. The plunger (20) and the handle (30) are attached or attachable to each other in a fixed manner, and the cannula (10) is arranged to be movable in the longitudinal direction, so that the plunger (20) is placed therein.

Abstract: Intravaginal delivery system including a flexible support means, and a delivery means carried by the support means and containing an active agent wherein the support means comprises a core member substantially in the form of an open ring, and the delivery means comprises at least one polymer body which encircles the core member in a beltwise manner along a portion of a length of the core member.